<!DOCTYPE html>
<html >

<head>

  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>Conferences 2016</title>
  <meta content="text/html; charset=UTF-8" http-equiv="Content-Type">
  <meta name="description" content="A guide to authoring books with R Markdown, including how to generate figures and tables, and insert cross-references, citations, HTML widgets, and Shiny apps in R Markdown. The book can be exported to HTML, PDF, and e-books (e.g. EPUB). The book style is customizable. You can easily write and preview the book in RStudio IDE or other editors, and host the book wherever you want (e.g. bookdown.org).">
  <meta name="generator" content="bookdown 0.0.79 and GitBook 2.6.7">

  <meta property="og:title" content="Conferences 2016" />
  <meta property="og:type" content="book" />
  <meta property="og:url" content="http://shanmdphd.github.io/Conferences/" />
  <meta property="og:image" content="http://shanmdphd.github.io/Conferences/images/cover.png" />
  <meta property="og:description" content="A guide to authoring books with R Markdown, including how to generate figures and tables, and insert cross-references, citations, HTML widgets, and Shiny apps in R Markdown. The book can be exported to HTML, PDF, and e-books (e.g. EPUB). The book style is customizable. You can easily write and preview the book in RStudio IDE or other editors, and host the book wherever you want (e.g. bookdown.org)." />
  <meta name="github-repo" content="shanmdphd/PAPER" />

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Conferences 2016" />
  
  <meta name="twitter:description" content="A guide to authoring books with R Markdown, including how to generate figures and tables, and insert cross-references, citations, HTML widgets, and Shiny apps in R Markdown. The book can be exported to HTML, PDF, and e-books (e.g. EPUB). The book style is customizable. You can easily write and preview the book in RStudio IDE or other editors, and host the book wherever you want (e.g. bookdown.org)." />
  <meta name="twitter:image" content="http://shanmdphd.github.io/Conferences/images/cover.png" />

<meta name="author" content="Sungpil Han">

<meta name="date" content="2016-07-14">

<script type="text/x-mathjax-config">
MathJax.Hub.Config({
  TeX: { equationNumbers: { autoNumber: "AMS" } }
});
</script>

  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black">
  
  
<link rel="prev" href="observational-study-pitfall-.html">
<link rel="next" href="-.html">

<script src="libs/jquery/jquery.min.js"></script>
<link href="libs/gitbook/css/style.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-fontsettings.css" rel="stylesheet" />










<link rel="stylesheet" href="css/style.css" type="text/css" />
</head>

<body>


  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="./">Conferences</a></li>

<li class="divider"></li>
<li class="chapter" data-level="1" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i><b>1</b> Introduction</a></li>
<li class="chapter" data-level="2" data-path="kscpt.html"><a href="kscpt.html"><i class="fa fa-check"></i><b>2</b> 2016 KSCPT</a><ul>
<li class="chapter" data-level="2.1" data-path="opening-remark.html"><a href="opening-remark.html"><i class="fa fa-check"></i><b>2.1</b> Opening Remark</a></li>
<li class="chapter" data-level="2.2" data-path="first-session.html"><a href="first-session.html"><i class="fa fa-check"></i><b>2.2</b> First Session</a><ul>
<li class="chapter" data-level="2.2.1" data-path="first-session.html"><a href="first-session.html#precision-medicine-a-clinical-pharmacological-perspective"><i class="fa fa-check"></i><b>2.2.1</b> 13:20~14:00 Precision Medicine: A Clinical Pharmacological Perspective</a></li>
<li class="chapter" data-level="2.2.2" data-path="first-session.html"><a href="first-session.html#the-role-of-pharmacogenomics-in-drug-development-regulatory-review-and-clinical-practice"><i class="fa fa-check"></i><b>2.2.2</b> 14:00~14:30 The role of pharmacogenomics in drug development, regulatory review and clinical practice</a></li>
<li class="chapter" data-level="2.2.3" data-path="first-session.html"><a href="first-session.html#the-liver-gut-microbiota-axis-modulates-inter-individual-variability-in-xenobiotic-disposition-and-toxicology"><i class="fa fa-check"></i><b>2.2.3</b> 14:30~15:00 The Liver-Gut Microbiota Axis Modulates Inter-Individual Variability in Xenobiotic Disposition and Toxicology</a></li>
</ul></li>
<li class="chapter" data-level="2.3" data-path="second-session.html"><a href="second-session.html"><i class="fa fa-check"></i><b>2.3</b> Second Session</a><ul>
<li class="chapter" data-level="2.3.1" data-path="second-session.html"><a href="second-session.html#the-role-of-stem-cells-in-discovery-and-validation-of-pharmacogenomic-markers"><i class="fa fa-check"></i><b>2.3.1</b> 15:20~15:50 The role of stem cells in discovery and validation of pharmacogenomic markers</a></li>
<li class="chapter" data-level="2.3.2" data-path="second-session.html"><a href="second-session.html#pharmacogenomics-and-epigenomics"><i class="fa fa-check"></i><b>2.3.2</b> 15:50~16:20 Pharmacogenomics and Epigenomics</a></li>
<li class="chapter" data-level="2.3.3" data-path="second-session.html"><a href="second-session.html#emerging-roles-of-human-cyp1b1-in-cancer-growth-and-metastasis"><i class="fa fa-check"></i><b>2.3.3</b> 16:20~16:50 Emerging roles of human CYP1B1 in cancer growth and metastasis</a></li>
<li class="chapter" data-level="2.3.4" data-path="second-session.html"><a href="second-session.html#omics-for-precision-medicine-clinical-implementation-in-oncology"><i class="fa fa-check"></i><b>2.3.4</b> 16:50~17:20 omics for precision Medicine : Clinical Implementation in oncology</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="3" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html"><i class="fa fa-check"></i><b>3</b> “Translation and Convergence for Future Medicine”</a><ul>
<li class="chapter" data-level="3.1" data-path="plenary-session-ii-rd-.html"><a href="plenary-session-ii-rd-.html"><i class="fa fa-check"></i><b>3.1</b> Plenary Session II “의료기술및 R&amp;D 변화의최신동향”</a><ul>
<li class="chapter" data-level="3.1.1" data-path="plenary-session-ii-rd-.html"><a href="plenary-session-ii-rd-.html#lecture-1--------"><i class="fa fa-check"></i><b>3.1.1</b> 13:30 ~ 14:15 Lecture 1 :의료분야에서의 빅데이터 :임상연구 및 진료를 위한 애널리틱스의 활용</a></li>
<li class="chapter" data-level="3.1.2" data-path="plenary-session-ii-rd-.html"><a href="plenary-session-ii-rd-.html#lecture-2----"><i class="fa fa-check"></i><b>3.1.2</b> 14:15 ~ 15:00 Lecture 2 :합성 항체에서 합성 단백질로</a></li>
</ul></li>
<li class="chapter" data-level="3.2" data-path="parallel-session-i-chairperson-.html"><a href="parallel-session-i-chairperson-.html"><i class="fa fa-check"></i><b>3.2</b> Parallel Session I “의료분야에서의빅데이터” Chairperson :김태원(서울아산병원임상의학연구소장) [대강당]</a><ul>
<li class="chapter" data-level="3.2.1" data-path="parallel-session-i-chairperson-.html"><a href="parallel-session-i-chairperson-.html#lecture-1------alexander-turchin-harvard-university-brigham-and-womens-hospital-usa"><i class="fa fa-check"></i><b>3.2.1</b> Lecture 1 :전자의무기록에 기반한 임상 빅데이터 연구 Alexander Turchin (Harvard University, Brigham and Women’s Hospital, USA)</a></li>
<li class="chapter" data-level="3.2.2" data-path="parallel-session-i-chairperson-.html"><a href="parallel-session-i-chairperson-.html#lecture-2----tom-lawry-microsoft-corp.-usa"><i class="fa fa-check"></i><b>3.2.2</b> Lecture 2 : 의료분야에서의 빅데이터 분석 Tom Lawry (Microsoft Corp., USA)</a></li>
<li class="chapter" data-level="3.2.3" data-path="parallel-session-i-chairperson-.html"><a href="parallel-session-i-chairperson-.html#lecture-3-------"><i class="fa fa-check"></i><b>3.2.3</b> Lecture 3 :생물기작 기반 암 오믹스 데이터 분석 기법</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="4" data-path="acrep.html"><a href="acrep.html"><i class="fa fa-check"></i><b>4</b> ACREP</a><ul>
<li class="chapter" data-level="4.1" data-path="observational-study.html"><a href="observational-study.html"><i class="fa fa-check"></i><b>4.1</b> Observational Study</a><ul>
<li class="chapter" data-level="4.1.1" data-path="observational-study.html"><a href="observational-study.html#contents"><i class="fa fa-check"></i><b>4.1.1</b> Contents</a></li>
</ul></li>
<li class="chapter" data-level="4.2" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html"><i class="fa fa-check"></i><b>4.2</b> Observational Study의 Pitfall 및 이를 극복하기 위한 방법</a><ul>
<li class="chapter" data-level="4.2.1" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html#experimental-study-yes"><i class="fa fa-check"></i><b>4.2.1</b> Experimental study? Yes</a></li>
<li class="chapter" data-level="4.2.2" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html#experimental-study-no"><i class="fa fa-check"></i><b>4.2.2</b> Experimental study? No</a></li>
<li class="chapter" data-level="4.2.3" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html#contents-1"><i class="fa fa-check"></i><b>4.2.3</b> Contents</a></li>
<li class="chapter" data-level="4.2.4" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html#conclusion"><i class="fa fa-check"></i><b>4.2.4</b> Conclusion</a></li>
</ul></li>
<li class="chapter" data-level="4.3" data-path="diagnostic-test-biomarker-study.html"><a href="diagnostic-test-biomarker-study.html"><i class="fa fa-check"></i><b>4.3</b> Diagnostic test &amp; Biomarker Study</a><ul>
<li class="chapter" data-level="4.3.1" data-path="diagnostic-test-biomarker-study.html"><a href="diagnostic-test-biomarker-study.html#contents---diagnostic-test"><i class="fa fa-check"></i><b>4.3.1</b> Contents - Diagnostic test</a></li>
<li class="chapter" data-level="4.3.2" data-path="diagnostic-test-biomarker-study.html"><a href="diagnostic-test-biomarker-study.html#contents---biomarker"><i class="fa fa-check"></i><b>4.3.2</b> Contents - Biomarker</a></li>
</ul></li>
<li class="chapter" data-level="4.4" data-path="-.html"><a href="-.html"><i class="fa fa-check"></i><b>4.4</b> 2차 자료원을 이용한 역학 연구군</a></li>
<li class="chapter" data-level="4.5" data-path="-clinical-prediction-model-individual-riskoutcome-probability-.html"><a href="-clinical-prediction-model-individual-riskoutcome-probability-.html"><i class="fa fa-check"></i><b>4.5</b> 대규모 이차 자료원을 이용한 clinical prediction model : individual risk/outcome probability 예측 분석법</a></li>
<li class="chapter" data-level="4.6" data-path="web-r-org.html"><a href="web-r-org.html"><i class="fa fa-check"></i><b>4.6</b> Web-r.org</a><ul>
<li class="chapter" data-level="4.6.1" data-path="web-r-org.html"><a href="web-r-org.html#contents-2"><i class="fa fa-check"></i><b>4.6.1</b> Contents</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="5" data-path="prism.html"><a href="prism.html"><i class="fa fa-check"></i><b>5</b> Prism</a><ul>
<li class="chapter" data-level="5.1" data-path="morning.html"><a href="morning.html"><i class="fa fa-check"></i><b>5.1</b> Morning</a><ul>
<li class="chapter" data-level="5.1.1" data-path="morning.html"><a href="morning.html#lim-covariate-model"><i class="fa fa-check"></i><b>5.1.1</b> Lim Covariate model</a></li>
<li class="chapter" data-level="5.1.2" data-path="morning.html"><a href="morning.html#fda---lee"><i class="fa fa-check"></i><b>5.1.2</b> FDA - Lee</a></li>
<li class="chapter" data-level="5.1.3" data-path="morning.html"><a href="morning.html#pfizer"><i class="fa fa-check"></i><b>5.1.3</b> Pfizer</a></li>
</ul></li>
<li class="chapter" data-level="5.2" data-path="prism-afternoon.html"><a href="prism-afternoon.html"><i class="fa fa-check"></i><b>5.2</b> PRISM Afternoon</a><ul>
<li class="chapter" data-level="5.2.1" data-path="prism-afternoon.html"><a href="prism-afternoon.html#kim"><i class="fa fa-check"></i><b>5.2.1</b> Kim</a></li>
<li class="chapter" data-level="5.2.2" data-path="prism-afternoon.html"><a href="prism-afternoon.html#strategic-application-of-pm-in-global-drug-development-experience-from-hanmi"><i class="fa fa-check"></i><b>5.2.2</b> Strategic application of PM in global drug development: Experience from Hanmi</a></li>
<li class="chapter" data-level="5.2.3" data-path="prism-afternoon.html"><a href="prism-afternoon.html#mbdd"><i class="fa fa-check"></i><b>5.2.3</b> MBDD</a></li>
<li class="chapter" data-level="5.2.4" data-path="prism-afternoon.html"><a href="prism-afternoon.html#pharmacometric-information-in-drug-label"><i class="fa fa-check"></i><b>5.2.4</b> Pharmacometric information in drug label</a></li>
<li class="chapter" data-level="5.2.5" data-path="prism-afternoon.html"><a href="prism-afternoon.html#pharmacometrics-in-dose-optimization"><i class="fa fa-check"></i><b>5.2.5</b> Pharmacometrics in Dose Optimization</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="6" data-path="mfds-asan-joint-symposium-on-rare-diseases-2016.html"><a href="mfds-asan-joint-symposium-on-rare-diseases-2016.html"><i class="fa fa-check"></i><b>6</b> MFDS-Asan Joint Symposium on Rare Diseases 2016</a><ul>
<li class="chapter" data-level="6.1" data-path="session-1-rare-diseases-in-korea-status-research-experiences.html"><a href="session-1-rare-diseases-in-korea-status-research-experiences.html"><i class="fa fa-check"></i><b>6.1</b> Session 1 Rare diseases in Korea : Status &amp; Research experiences</a><ul>
<li class="chapter" data-level="6.1.1" data-path="session-1-rare-diseases-in-korea-status-research-experiences.html"><a href="session-1-rare-diseases-in-korea-status-research-experiences.html#national-support-for-rare-disease-current-status-and-future-prospects"><i class="fa fa-check"></i><b>6.1.1</b> National support for rare disease : Current status and future prospects</a></li>
<li class="chapter" data-level="6.1.2" data-path="session-1-rare-diseases-in-korea-status-research-experiences.html"><a href="session-1-rare-diseases-in-korea-status-research-experiences.html#translational-research-for-drug-development-historical-perspective"><i class="fa fa-check"></i><b>6.1.2</b> Translational research for drug development : Historical perspective</a></li>
</ul></li>
<li class="chapter" data-level="6.2" data-path="session-2-global-regulatory-experiences-in-orphan-drug-development.html"><a href="session-2-global-regulatory-experiences-in-orphan-drug-development.html"><i class="fa fa-check"></i><b>6.2</b> Session 2 Global regulatory experiences in orphan drug development</a><ul>
<li class="chapter" data-level="6.2.1" data-path="session-2-global-regulatory-experiences-in-orphan-drug-development.html"><a href="session-2-global-regulatory-experiences-in-orphan-drug-development.html#considerations-for-drug-development-for-rare-diseases-cases-of-inborn-errors-of-metabolism"><i class="fa fa-check"></i><b>6.2.1</b> Considerations for drug development for rare diseases : Cases of inborn errors of metabolism</a></li>
<li class="chapter" data-level="6.2.2" data-path="session-2-global-regulatory-experiences-in-orphan-drug-development.html"><a href="session-2-global-regulatory-experiences-in-orphan-drug-development.html#role-of-pharmacometrics-in-the-development-of-orphan-drugs"><i class="fa fa-check"></i><b>6.2.2</b> Role of pharmacometrics in the development of orphan drugs</a></li>
</ul></li>
<li class="chapter" data-level="6.3" data-path="session-3-lessons-and-learned-rd-for-rare-disease.html"><a href="session-3-lessons-and-learned-rd-for-rare-disease.html"><i class="fa fa-check"></i><b>6.3</b> Session 3 Lessons and learned : R&amp;D for rare disease</a></li>
<li class="chapter" data-level="6.4" data-path="session-4-asan-initia-tives-for-rare-disease.html"><a href="session-4-asan-initia-tives-for-rare-disease.html"><i class="fa fa-check"></i><b>6.4</b> Session 4 Asan initia tives for rare disease</a></li>
</ul></li>
<li class="divider"></li>
<li><a href="http://shanmdphd.github.io">Back to shanmdphd.github.io</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">Conferences 2016</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="diagnostic-test-biomarker-study" class="section level2">
<h2><span class="header-section-number">4.3</span> Diagnostic test &amp; Biomarker Study</h2>
<ul>
<li>Speaker: 박성호 - 영상의학과</li>
</ul>
<div id="contents---diagnostic-test" class="section level3">
<h3><span class="header-section-number">4.3.1</span> Contents - Diagnostic test</h3>
<ul>
<li>DTA sutdy</li>
<li>Prevalence낮으면</li>
<li>횡으로 본다. Predictive Value - Prevalence에 영향을 받는다. Pre올라가면 PPV올라가. NPV낮아져.</li>
<li>odds ratio - prevalence에 영향을 안받는다. intrinsic parameter로 많이 씀.</li>
<li>case-control study vs cross-sectional study [옛날 용어]</li>
<li>Cochrane - case-control type accuracy study vs cohort type accuracy study</li>
<li>NECA - diagnostic case-control study vs diagnostic cohort study</li>
<li>Area under ROC curve - C statistics</li>
<li>Youden index - sens spec 더해서 빼기 1 Youden J statistic</li>
<li>Least Euclidean distance from (0,1) 거리가 최소되는 점. - 쉬운개념</li>
<li>diagnostic accuracy - 시각적으로 어떻게 구성하는지가 중요함.</li>
<li>McNemar test</li>
<li>Comparing two proportions (2x2) - unpaired(fisher,Chi2), paired (McNemar)</li>
</ul>
</div>
<div id="contents---biomarker" class="section level3">
<h3><span class="header-section-number">4.3.2</span> Contents - Biomarker</h3>
<ul>
<li>Biomarker
<ul>
<li>Classifier / Prognostic / Predictive / Monitoring</li>
</ul></li>
<li>Petal et al. MRI-detected tumor response for locally advanced rectal cancer predicts survival outcomes</li>
<li>Machtay et al. Prediction of survival
<ul>
<li>Prospective</li>
<li>S III lung cancer eligible for CCRT</li>
<li>Endpoint : overall survival</li>
<li>SUV</li>
</ul></li>
<li>Hylton et al.
<ul>
<li>Prospective</li>
<li>Index: functional tumor volume measured with pre-surgery breast MRI</li>
<li>Comparator: post-surgical pathologic complete response(PCR)</li>
<li>Modified C-statistics(ROC) - diagnosis는 있다 없다로 나온다. survival은 time to event - 각각의 time point마다 diagnosis 유사한 통계량이 나와서 그걸 summation</li>
</ul></li>
<li>Studies of predictive accuracy
<ul>
<li>Two approaches - Time-to-event / event by a fixed time</li>
<li>Event by a fixed time - Sn Sp ROC - Accuracy study와 유사한 것으로 된다.</li>
</ul></li>
<li>더 impact있는 것. - randomization을 테스트 후에 할 것인가 아니면 전에 할 것인가? 전에 하는 것이 더 임팩트 있다. 왜냐하면 테스트(+)이면 치료 들어가는 경우가 많기 때문이다.</li>
<li>후자에 해당하는 (더 임팩트있는) 스터디의 예.</li>
<li>Monitoring biomarker
<ul>
<li>Correlation between x and y / delta x and delta y</li>
<li>Delta를 보는 것이 중요하다.</li>
</ul></li>
</ul>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="observational-study-pitfall-.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="-.html" class="navigation navigation-next " aria-label="Next page""><i class="fa fa-angle-right"></i></a>

<script src="libs/gitbook/js/app.min.js"></script>
<script src="libs/gitbook/js/lunr.js"></script>
<script src="libs/gitbook/js/plugin-search.js"></script>
<script src="libs/gitbook/js/plugin-sharing.js"></script>
<script src="libs/gitbook/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook/js/plugin-bookdown.js"></script>
<script src="libs/gitbook/js/jquery.highlight.js"></script>
<script>
require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"facebook": true,
"twitter": true,
"google": false,
"weibo": false,
"instapper": false,
"vk": false,
"all": ["facebook", "google", "twitter", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": "https://github.com/shanmdphd/shanmdphd.github.io/edit/master/_ConferencesSource/2016-06-24-ACREP.rmd",
"text": "Edit"
},
"download": ["bookdown.pdf", "bookdown.epub", "bookdown.mobi"],
"toc": {
"collapse": "subsection"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    if (location.protocol !== "file:" && /^https?:/.test(script.src))
      script.src  = script.src.replace(/^https?:/, '');
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
